Evidence map›Paper›PMID 37790858›Full record

ArticleCurrent research in food science2023

Rational design of an N-terminal cysteine-containing tetrapeptide that inhibits tyrosinase and evaluation of its mechanism of action.

Anupong Joompang, Preeyanan Anwised, Sompong Klaynongsruang, Lapatrada Taemaitree, Anuwat Wanthong, Kiattawee Choowongkomon, Sakda Daduang, Somporn Katekaew, Nisachon Jangpromma

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current research in food science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Anupong JoompangDepartment of Biochemistry, Faculty of Science, Khon Kaen University, Khon Kaen, 40002, Thailand.
Preeyanan AnwisedProtein and Proteomics Research Center for Commercial and Industrial Purposes (ProCCI), Faculty of Science, Khon Kaen University, Khon Kaen, 40002, Thailand.
Sompong KlaynongsruangDepartment of Biochemistry, Faculty of Science, Khon Kaen University, Khon Kaen, 40002, Thailand.
Lapatrada TaemaitreeDepartment of Integrated Science, Faculty of Science, Khon Kaen University, Khon Kaen, 40002, Thailand.
Anuwat WanthongProtein and Proteomics Research Center for Commercial and Industrial Purposes (ProCCI), Faculty of Science, Khon Kaen University, Khon Kaen, 40002, Thailand.
Kiattawee ChoowongkomonDepartment of Biochemistry, Faculty of Science, Kasetsart University, Bangkok, 10900, Thailand.
Sakda DaduangProtein and Proteomics Research Center for Commercial and Industrial Purposes (ProCCI), Faculty of Science, Khon Kaen University, Khon Kaen, 40002, Thailand.
Somporn KatekaewDepartment of Biochemistry, Faculty of Science, Khon Kaen University, Khon Kaen, 40002, Thailand.
Nisachon JangprommaDepartment of Biochemistry, Faculty of Science, Khon Kaen University, Khon Kaen, 40002, Thailand.
Khon Kaen University · THKasetsart University · THMahasarakham University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There has been a resurgence of interest in bioactive peptides as therapeutic agents. This is particularly interesting for tyrosinase, which can be inhibited by thiol-containing peptides. This work demonstrates that an N-terminal cysteine-containing tetrapeptide can be rationally designed to inhibit tyrosinase activity

Indexed as

DepigmentationEnzyme kineticsModified peptideMolecular dockingTetrapeptideTyrosinase inhibitor

Identifiers

PMID37790858
PMCPMC10543783
OpenAlexW4386913657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.